NEW YORK, April 11, 2013 /PRNewswire-iReach/ -- SOTIO a.s, a leader in cell therapy treatments for cancer and autoimmune diseases, has added to their senior leadership team with the addition of Heidi M. Hagen as Chief Operating Officer-US and Head of Global Operations Strategy. As the strategic advisor to SOTIO, Epsen Fuller Group completed the successful placement, which encompassed an exhaustive search of the top operational leaders in biotechnology, and specifically cell manufacturing.
"This role is very narrowly focused on cutting-edge therapies based on activated dendritic cells that trigger the immune system for the treatment of cancer and autoimmune diseases", explained Thomas Fuller , Managing Partner of Epsen Fuller Group and leader on his project.
Ms. Hagen is an expert in dendritic cell manufacturing and autologous operations as evidenced in her most recent role as SVP, Operations at Dendreon. Heidi's achievements there were numerous, including building three state-of-the-art, and very high-performing manufacturing facilities, on budget and on schedule. Heidi was formerly at Immunex Corporation, acquired by Amgen, where she held leadership positions in supply chain, clinical operations, and business strategy. Holding an MBA, an MS in Bioengineering, and a BS in cell and molecular biology, all from the University of Washington, Heidi is a widely-recognized authority on cell manufacturing.
"Sotio is focused on becoming a leader in the field of modern biotechnology therapies and related science," says Mr. Fuller. "We were looking for an individual with the real drive and passion to lead the way in commercializing the science of cell manufacturing, thereby enabling SOTIO to flourish as an innovative and fast-growth orga
|SOURCE Epsen Fuller Group|
Copyright©2012 PR Newswire.
All rights reserved